Monoamine oxidase b inhibitors for use in prevention or treatment of prostate cancer

A monoamine oxidase and prostate cancer technology, applied in the field of monoamine oxidase B inhibitors used in the prevention or treatment of prostate cancer, can solve the problem of weak MAO-A activity, no suggestion for prostate cancer treatment, no experimental data on MAO-B inhibition effect, etc. question

Pending Publication Date: 2022-04-19
TOXIE EURO INTELLIGENS KÉMIAI SZENZOROKAT KUTATÓ, FEJLESZTÓ KORLÁTOLT FELELÓSSEGÚ TÁRSASÁG
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the case of MAO-B-selective selegiline, MAO-B-selective selegiline has long been not recommended for prostate cancer due to its lesser effect on prostate cancer cell lines (based on in vitro experiments) cancer treatment
Published in 2019 (S.Gaur et al., Prostate, 2019, 79, 667-677) discussing the effect of MAO-A inhibitors on prostate cancer (see title: "Monoamine oxidase A (MAO-A) inhibitors on androgen Sensitive prostate cancer cells and the effect of castration-resistant prostate cancer cells (Effect of Monoamine oxi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoamine oxidase b inhibitors for use in prevention or treatment of prostate cancer
  • Monoamine oxidase b inhibitors for use in prevention or treatment of prostate cancer
  • Monoamine oxidase b inhibitors for use in prevention or treatment of prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0055] The term "MAO-B inhibitor compound" includes salts (preferably HCl or sulfate), hydrates and any isomers or mixtures thereof of the compound in question. Furthermore, "MAO-B inhibitor compound" refers to the active ingredient at a concentration that exerts significant MAO-B inhibition (preferably only slightly or negligibly inhibits the MAO-A enzyme), i.e., the MAO-B inhibitor compound is Selective MAO-B inhibitors. "MAO-B inhibitor compound" is preferably selected from selegiline, rasagiline and safinamide, wherein selegiline and rasagiline are preferred, selegiline (also known as (- )-propargyl) is particularly preferred.

[0056] The dosage form of the pharmaceutical compositions of the present invention ("compositions" for short) is not critical, so they can be administered orally, intravenously, intramuscularly, parabulbarly, retrobulbarly, subtenon, Administration is intracameral, intravitreal and other injection forms, but can also be administered sublingually ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a monoamine oxidase B (MAO-B) inhibitor compound for use in the prevention or treatment of prostate cancer (PCa) wherein a selective MAO-A inhibitor compound is not co-administered. In use, other agents for the treatment of prostate cancer are administered together or alternately with the selective compound MAO-B, and/or radiation therapy is used together or alternately with the selective compound MAO-B for the treatment of prostate cancer. A further aspect of the invention is the use of MAO-B inhibitor compounds in the manufacture of a medicament for the treatment of prostate cancer.

Description

[0001] The present invention relates to the use of monoamine oxidase-B (MAO-B) enzyme inhibitors, in particular selegiline and rasagiline, in the treatment of prostate cancer (PCa) and in the manufacture of Uses in medicine. Background technique [0002] Prostate cancer is one of the most common neoplastic diseases in men, and PCa is the second most common neoplastic disease after lung cancer in terms of the number of new cases diagnosed so far. For men, prostate cancer is one of the most common causes of death globally and the second most common cause of cancer death in Western societies (Shih 2018); moreover, the incidence of prostate cancer is increasing. [0003] Prostate cancer is also an important area from a veterinary point of view, and this disease is particularly noteworthy in the case of dogs and horses: it can be seen that the incidence of prostate cancer has increased among neoplastic diseases (https: / / wearethcure .org / learn-more-about-canince-cancer / canine-cance...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/135A61K31/137A61K31/337A61P35/00A61P35/04
CPCA61K45/06A61K31/137A61K31/135A61K31/337A61P35/00A61P35/04A61K2300/00
Inventor 维多利亚·加什纳尔内·科尔莫斯塔马斯·卡莱拉斯洛·曼格尔彼得·马修斯安妮塔·斯泰布兹苏萨纳·塔马西克内·海利斯
Owner TOXIE EURO INTELLIGENS KÉMIAI SZENZOROKAT KUTATÓ, FEJLESZTÓ KORLÁTOLT FELELÓSSEGÚ TÁRSASÁG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap